Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biochem Pharmacol ; 59(5): 591-6, 2000 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-10660125

RESUMEN

Human CC chemokine receptor 1 (CCR1) has been proposed as a receptor for CKbeta8. To obtain conclusive evidence, binding-displacement studies of 125I-CKbeta8 (25-99) were performed on membranes of Chinese hamster ovary cells expressing human CCR1. The Ic50 for displacement of 125I-CKbeta8 (25-99) with CKbeta8 (25-99) was 0.22 nM. The longer forms of CKbeta8 (24-99 and 1-99) also displaced 125I-CKbeta8, with Ic50 values of 6.5 and 16 nM, respectively. Displacement profiles of 125I-CKbeta8 (25-99) on freshly prepared human monocytes indicated that CCR1 was the major receptor for CKbeta8. We conclude that CCR1 is a receptor for different-length CKbeta8 and that CKbeta8 (25-99) has a similar affinity for CCR1 as macrophage inflammatory protein-1alpha (MIP-1alpha). The longer variants of CKbeta8 are significantly less potent than CKbeta8 (25-99) and MIP-1a on CCR1 and monocytes (P < 0.05).


Asunto(s)
Quimiocinas CC/metabolismo , Receptores de Quimiocina/metabolismo , Animales , Unión Competitiva , Células CHO , Cricetinae , Humanos , Radioisótopos de Yodo , Monocitos/metabolismo , Péptidos/metabolismo , Receptores CCR1 , Transfección
2.
Atherosclerosis ; 141(2): 237-47, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9862172

RESUMEN

Although numerous transgenic mouse models for atherosclerosis have been developed recently, little is known about their response to hypolipidaemic or anti-atherosclerotic agents. We investigated the effect of the known hypocholesterolaemic and anti-atherosclerotic drug probucol on serum lipids, lipoproteins and atherosclerosis in fat-fed low density lipoprotein (LDL) receptor deficient mice. Probucol at doses of 0.2 and 1% in the diet which are similar to those used in the mouse by other investigators reduced serum cholesterol by 26 and 37%, respectively. Probucol also reduced serum triglyceride levels by 33 and 47% at doses of 0.2 and 1%, respectively. The decrease in serum cholesterol and triglycerides was mainly due to a decrease of these lipids in VLDL and or chylomicrons. Despite these potentially beneficial changes in serum lipids atherosclerotic lesion areas in the aortic root were unchanged in the probucol treated mice. After 12 weeks treatment most of the mice receiving probucol had swollen feet and tails due to oedema. Histological examination of the base of the hearts from the probucol treated mice revealed lipid droplets within the reticuloendothelial and other interstitial cells. There was also an interstitial subacute inflammatory cell infiltration associated with the lipid deposition. The oedema induced by probucol could be the result of cardiac insufficiency due to interstitial lipidosis and inflammation in the base of the heart together with the extensive atherosclerotic lesions in the aortic sinus.


Asunto(s)
Anticolesterolemiantes/farmacología , Arteriosclerosis/patología , Grasas de la Dieta/administración & dosificación , Lípidos/sangre , Probucol/farmacología , Receptores de LDL/deficiencia , Animales , Anticolesterolemiantes/toxicidad , Aorta/patología , Colesterol/sangre , Femenino , Ratones , Probucol/toxicidad , Triglicéridos/sangre
3.
N Engl J Med ; 292(2): 112, 1975 Jan 09.
Artículo en Inglés | MEDLINE | ID: mdl-1109435
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA